Transurethral Incision of Bladder Neck Contracture (TUIBNC)
Transurethral incision of bladder neck contracture (TUIBNC) is the first-line endoscopic operation for bladder neck contracture (BNC) and post-prostatectomy vesicourethral anastomotic stenosis (VUAS). The standardized technique — balloon dilation followed by deep bilateral incisions at 3 and 9 o'clock — achieves single-procedure patency rates of 72–82% and cumulative success of 86–94% after two procedures.[1][2]
For the broader BNC framework, decision matrix, and treatment database, see Bladder Neck Contracture. For VUAS-specific reconstruction context, see VUAS. For open / robotic reconstruction options, see Y-V Plasty, T-Plasty, and Combined Abdominoperineal Approach.
Definition and Indications
BNC is fibrotic narrowing of the bladder neck, typically presenting at median 5.8 months after prostate surgery with obstructive LUTS, decreased flow, and elevated PVR.[3] Most common etiologies:
- Radical prostatectomy ± radiation — the dominant cause in referral series.[1]
- TURP (especially bipolar, ~4.7% incidence) and HoLEP (~1.3%).[3]
- Other endoscopic prostate procedures.
The AUA Urethral Stricture Disease Guideline (2023) establishes that bladder-neck incision and bladder-neck resection have comparable outcomes — choice may be guided by surgeon preference and visualization.[4]
Standardized Surgical Technique
The Nealon / Ramirez technique — used in the largest contemporary series — is the canonical standardized approach.[1][2]
- Initial dilation. A 24 Fr balloon dilator is used to dilate the contracture and allow passage of the resectoscope.
- Deep bilateral lateral incisions. A Collins knife (cold knife or electrocautery) is used to make deep incisions at the 3 and 9 o'clock positions, extending through the scar tissue into the perivesical fat. Lateral positioning avoids the neurovascular bundles and the external urinary sphincter.
Variations
| Variant | Notes |
|---|---|
| Holmium laser incision | Comparable outcomes to Collins-knife incision; useful for day-surgery models[6][7] |
| Adjunctive intralesional injection (corticosteroids, mitomycin-C) | Variable utility — see below |
| TUIBN + transverse mucosal realignment (Abramowitz endoscopic Y-V plasty) | 89% single-procedure success; 100% with second procedure; no de novo incontinence[8] |
| Tri-radial or quadrant-radial incisions | Alternative to bilateral 3 and 9 o'clock — used in some MMC protocols[9] |
The Nealon 2022 series of 123 patients demonstrated that deep bilateral incisions alone (no intralesional agents) achieve comparable patency rates to series using MMC or corticosteroids — raising the question of whether the incision technique itself drives most of the success.[1]
Outcomes
| Series | n | Technique | 1-procedure success | Cumulative success | Follow-up |
|---|---|---|---|---|---|
| Nealon 2022[1] | 123 | Balloon dilation + Collins knife at 3 & 9 o'clock | 82.1% | 94.3% (2 procedures) | 12 mo |
| Ramirez 2013[2] | 50 (78% refractory) | Deep lateral incisions | 72% | 86% (2 procedures) | 12.9 mo |
| Rosenbaum 2021[10] | 60 (post-BPH) | Incision or resection | 53% overall | — | Variable |
| Abramowitz 2021[8] | 19 | TUIBN + mucosal realignment | 89% | 100% (2 procedures) | 6 mo |
| Quarta 2025[11] | 110 | Ho-laser BNI (91.8%) | 64% mild IPSS at 3 mo | — | 3 mo |
The AUA guidelines note first-time VUAS treatment is successful in ~50–80% of cases, with all endoscopic techniques showing similar success.[4]
Risk Factors for Failure
| Risk factor | Significance |
|---|---|
| ≥ 2 prior endoscopic BNC procedures | Most consistently identified across studies (p = 0.03)[1][2] |
| >10 pack-year smoking | p = 0.039[2] |
| Prior pelvic radiation | Lower success; prospective data lacking[4] |
| Shorter interval between prostate surgery and BNC onset | < 6 months in some analyses[10][11] |
| Smaller prostate volume at initial BPE surgery | Predictor of failure[11] |
Complications
- Stress urinary incontinence (SUI) — the principal concern. Up to 78% of post-prostatectomy BNC patients have concomitant SUI; counsel about de novo or worsened incontinence after TUIBNC.[2][4]
- Urge incontinence — ~15% in some series.[6]
- Recurrence — 18–47% after a single procedure, typically within the first months (median ~1.8 mo).[10][11]
- Bleeding, UTI — uncommon; standard endoscopic risks.
Concomitant SUI and Subsequent AUS Placement
For patients with SUI after TUIBNC, AUS placement can be safely performed at an average of 2.9 months after TUIBNC. Only 8% (2/26) required repeat transurethral procedures for recurrent BNC after AUS placement — indicating > 90% long-term urethral patency.[2]
Adjunctive Pharmacotherapy — Mitomycin-C vs Corticosteroids
Both adjuncts are widely used; no head-to-head RCT exists. The Pang 2021 meta-analysis of 13 RCTs found MMC has the lowest stricture-recurrence odds among all adjuncts (intralesional OR 0.23, 95% CI 0.11–0.48, p < 0.001), but the safety profile differs materially.[12]
Mitomycin-C (MMC)
Antiproliferative / antifibrotic — inhibits fibroblast proliferation and collagen deposition.
Technique: Cold-knife tri- or quadrant-radial incisions followed by intralesional MMC injection at each incision site. Common dosing: 0.3–0.4 mg/mL in 0.2–0.4 mL aliquots at each site, or 2 mg total in 5 mL sterile water. Many protocols include 1 month of daily CIC postoperatively.[9][13][14][15]
| Series | n | Population | 1-proc success | Cumulative | Follow-up |
|---|---|---|---|---|---|
| Vanni 2011[9] | 18 | All failed prior incision | 72% | 89% (2 proc) | 12 mo |
| Rozanski 2021[16] | 86 | 91% failed prior DVIU | 65% | 90% (≥ 2 proc) | 21.1 mo |
| Sourial 2017[17] | 29 | Recurrent VUAS post-RP | 79% | 86% (with salvage) | 12 mo |
| Hacker 2022[18] | 51 | Post-prostate-cancer BNC/VUAS | 45% | 84% (up to 4 proc) | 32 mo |
| Farrell 2015[15] | 37 | Recurrent strictures / BNC | 75.7% | — | 23 mo |
| TURNS Redshaw 2015[19] | 55 | 80% failed prior | 58% | 75% (2 proc) | 9.2 mo |
Radiation effect: nonradiated patients consistently outperform radiated. Rozanski 2021: 94% vs 76% overall success (p = 0.04).[16] Hacker 2022: RP + EBRT had shortest interval to recurrence (p = 0.018).[18]
Safety flag — TURNS multicenter study: 7% (4/55) experienced serious adverse events related to MMC, with 3 patients needing or planning cystectomy.[19] Other series report no long-term MMC-attributable complications.[16][18][15] The AUA 2023 guideline acknowledges conflicting data about MMC for VUAS and recommends further study.[4]
Corticosteroids (Triamcinolone Acetonide, Betamethasone)
Suppress inflammatory cascade; reduce fibroblast activity and collagen synthesis. Used for BNC since the 1970s.[20]
Technique: intralesional injection of triamcinolone acetonide 40 mg/mL, 2 mL total at multiple sites (commonly 8 injection points) at incision / resection sites. A distinguishing feature of some protocols is repeated postoperative cystoscopy-guided injections every 4 weeks × 3 sessions.[21][22]
| Series | n | Population | Success | Follow-up |
|---|---|---|---|---|
| Zhang 2021[21] | 28 | Highly recurrent BNC (multiple prior failures) | 92.9% | 2.8 yr |
| Sun 2022[22] | 46 | BNC post-TURP/PVP (GreenLight + TA) | 100% (no recurrence) | NS |
| Wu 2024[3] | 20 | BNC post-TURP/TUEP (TUIBN + betamethasone) | 65% | 35.8 mo |
| Farah 1979[20] | 7 | Recurrent vesical neck contracture | 100% | NS |
| Kravchick 2013[23] | 14 | Recurrent anastomotic stenosis post-RP (TRUS-guided) | Lowest re-treatment rate | NS |
Mechanism advantage: Sun 2022 immunohistochemistry showed repeated triamcinolone injections significantly reduce collagen I, MMP-3, and TGF-β expression — providing mechanistic rationale.[22]
Safety: generally well tolerated. UTI 2.9–14%, bleeding 8.8%, extravasation 5.8%; no serious systemic adverse events reported. No risk of severe tissue necrosis that has been associated with MMC in rare cases.[12]
Summary table
| Domain | MMC | Corticosteroids |
|---|---|---|
| Meta-analysis effect | Lowest recurrence odds (OR 0.23; Pang 2021)[12] | Prolong time to recurrence; modest reduction[24] |
| Best-series success (recurrent BNC) | 89% cumulative (Vanni 2011)[9] | 92.9% (Zhang 2021 with repeat injections)[21] |
| Effect of radiation | Lower (76%) but meaningful[16] | Sparse data |
| Serious AEs | 7% in TURNS — including cystectomy[19] | None reported[12] |
| Repeat dosing | Single injection at incision | Postoperative serial injections are a unique feature of the Zhang / Sun protocols[21][22] |
| AUA 2023 stance | Conflicting data — further study needed[4] | Not specifically addressed |
Critical comparator — Nealon 2022
The Nealon series demonstrated that standardized deep bilateral incisions alone — no intralesional agent — achieve 82% single-procedure and 94% two-procedure success in 123 patients. These rates are comparable to MMC and corticosteroid series.[1]
This suggests the incision technique itself (deep bilateral 3 & 9 o'clock through scar into perivesical fat) is the primary determinant of success. Adjuncts may have added value in highly recurrent / radiated cases but should be selected with attention to MMC's serious-AE profile.
Recalcitrant BNC Pathway
For patients who fail repeated endoscopic treatment, the AUA 2023 guideline recommends considering robotic or open reconstruction (Conditional, Grade C).[4] Robotic reconstruction patency rates: 72.7–75%, with significant subsequent SUI requiring AUS implantation. Treatment must be tailored to patient preference, prior radiotherapy history, and existing incontinence. See Y-V Plasty, T-Plasty, and Combined Abdominoperineal Approach.
Key Principles
- Standardized deep bilateral incisions at 3 and 9 o'clock through scar into perivesical fat is the workhorse — Nealon 2022 reports 82% / 94% success at 1 / 2 procedures.[1]
- Bladder-neck incision and resection are comparable per AUA 2023 — surgeon preference governs choice.[4]
- Most consistent failure predictor: ≥ 2 prior endoscopic BNC procedures.[1][2]
- Smoking (> 10 pack-years) and pelvic radiation are additional failure risk factors.[2][4]
- Up to 78% of post-prostatectomy BNC patients have concomitant SUI — counsel about de novo / worsened incontinence; AUS can be safely placed ~3 months later with > 90% urethral patency preserved.[2]
- Adjuncts work but are not mandatory — Nealon 2022 demonstrated that the incision technique itself accounts for most of the success.[1]
- MMC has the lowest meta-analytic recurrence odds but a 7% serious-AE rate (TURNS) including cases requiring cystectomy; AUA notes conflicting data.[12][19][4]
- Corticosteroids — particularly with repeat postoperative injections (Zhang protocol) — achieve high success in recurrent BNC with no serious systemic AEs.[21][22]
- Endoscopic Y-V (Abramowitz 2021) — transverse mucosal realignment — is a promising bridging technique with 89% / 100% success and no de novo incontinence.[8]
- After 2 endoscopic failures, escalate to robotic / open reconstruction; tailor to radiation history and pre-existing incontinence.[4]
References
1. Nealon SW, Bhanvadia RR, Badkhshan S, et al. Transurethral incisions for bladder neck contracture: comparable results without intralesional injections. J Clin Med. 2022;11(15):4355. doi:10.3390/jcm11154355.
2. Ramirez D, Zhao LC, Bagrodia A, et al. Deep lateral transurethral incisions for recurrent bladder neck contracture: promising 5-year experience using a standardized approach. Urology. 2013;82(6):1430-5. doi:10.1016/j.urology.2013.08.018.
3. Wu MH, Liu JX, Zhang YF, et al. Bladder neck contracture following transurethral surgery of prostate: a retrospective single-center study. World J Urol. 2024;42(1):14. doi:10.1007/s00345-023-04715-2.
4. Wessells H, Morey A, Souter L, Rahimi L, Vanni A. Urethral stricture disease guideline amendment (2023). J Urol. 2023;210(1):64-71. doi:10.1097/JU.0000000000003482.
6. Sun J, Xia SQ, Tong Z, Xiao DD, Chen B. Transurethral columnar balloon dilation of the prostate combined with holmium laser incision for bladder neck contracture in day-surgery mode. Lasers Med Sci. 2023;38(1):279. doi:10.1007/s10103-023-03942-8.
7. Good DW, Nahas B, Phipps S, et al. Prostate benign prostatic hyperplasia. Chapter 27.
8. Abramowitz DJ, Balzano FL, Ruel NH, Chan KG, Warner JN. Transurethral incision with transverse mucosal realignment for the management of bladder neck contracture and vesicourethral anastomotic stenosis. Urology. 2021;152:102-108. doi:10.1016/j.urology.2021.02.035.
9. Vanni AJ, Zinman LN, Buckley JC. Radial urethrotomy and intralesional mitomycin C for the management of recurrent bladder neck contractures. J Urol. 2011;186(1):156-60. doi:10.1016/j.juro.2011.03.019.
10. Rosenbaum CM, Vetterlein MW, Fisch M, et al. Contemporary outcomes after transurethral procedures for bladder neck contracture following endoscopic treatment of benign prostatic hyperplasia. J Clin Med. 2021;10(13):2884. doi:10.3390/jcm10132884.
11. Quarta L, Bandini M, Corsini C, et al. Assessing predictors of failure after bladder neck incision in patients who developed bladder neck stenosis following transurethral surgery for benign prostatic enlargement. Prostate. 2025. doi:10.1002/pros.70027.
12. Pang KH, Chapple CR, Chatters R, et al. A systematic review and meta-analysis of adjuncts to minimally invasive treatment of urethral stricture in men. Eur Urol. 2021;80(4):467-479. doi:10.1016/j.eururo.2021.06.022.
13. Klein R, Vasan R, Guercio C, Rusilko P. Minimally invasive management of posterior urethral stricture / stenosis with DVIU and mitomycin C injection. Urology. 2024;183:e317-e319. doi:10.1016/j.urology.2023.10.006.
15. Farrell MR, Sherer BA, Levine LA. Visual internal urethrotomy with intralesional mitomycin C and short-term clean intermittent catheterization for the management of recurrent urethral strictures and bladder neck contractures. Urology. 2015;85(6):1494-9. doi:10.1016/j.urology.2015.02.050.
16. Rozanski AT, Zhang LT, Holst DD, et al. The effect of radiation therapy on the efficacy of internal urethrotomy with intralesional mitomycin C for recurrent vesicourethral anastomotic stenoses and bladder neck contractures: a multi-institutional experience. Urology. 2021;147:294-298. doi:10.1016/j.urology.2020.09.035.
17. Sourial MW, Richard PO, Bettez M, Jundi M, Tu LM. Mitomycin-C and urethral dilatation: a safe, effective, and minimally invasive procedure for recurrent vesicourethral anastomotic stenoses. Urol Oncol. 2017;35(12):672.e15-672.e19. doi:10.1016/j.urolonc.2017.07.031.
18. Hacker EC, Maganty A, Pere MM, Rusilko PJ. Outcomes of vesicourethral anastomotic stenosis and bladder neck contracture with direct visual internal urethrotomy with mitomycin-C after prostate cancer treatment. Urology. 2022;165:331-335. doi:10.1016/j.urology.2022.01.041.
19. Redshaw JD, Broghammer JA, Smith TG, et al. Intralesional injection of mitomycin C at transurethral incision of bladder neck contracture may offer limited benefit: TURNS Study Group. J Urol. 2015;193(2):587-92. doi:10.1016/j.juro.2014.08.104.
20. Farah RN, DiLoreto RR, Cerny JC. Transurethral resection combined with steroid injection in treatment of recurrent vesical neck contractures. Urology. 1979;13(4):395-7. doi:10.1016/0090-4295(79)90338-8.
21. Zhang L, Liu S, Wu K, Mu X, Yang L. Management of highly recurrent bladder neck contractures via transurethral resection combined with intra- and post-operative triamcinolone acetonide injections. World J Urol. 2021;39(2):527-532. doi:10.1007/s00345-020-03224-w.
22. Sun X, Jin X, Leng K, Zhao Y, Zhang H. 180-W GreenLight laser photoselective vaporization with multiple triamcinolone acetonide injections for the treatment of bladder neck contractures. Lasers Med Sci. 2022;37(8):3115-3121. doi:10.1007/s10103-022-03568-2.
23. Kravchick S, Lobik L, Peled R, Cytron S. Transrectal ultrasonography-guided injection of long-acting steroids in the treatment of recurrent / resistant anastomotic stenosis after radical prostatectomy. J Endourol. 2013;27(7):875-9. doi:10.1089/end.2012.0661.
24. Zhang K, Qi E, Zhang Y, Sa Y, Fu Q. Efficacy and safety of local steroids for urethra strictures: a systematic review and meta-analysis. J Endourol. 2014;28(8):962-8. doi:10.1089/end.2014.0090.